Dr. O'Shaughnessy immediately adopted the Prosigna ROR score from the OPTIMA trial to guide chemotherapy decisions, even in patients with 4-9 positive lymph nodes, trusting tumor biology over high-risk anatomical features.
To mitigate diarrhea with adjuvant abemaciclib, clinicians start at a lower dose (50mg BID) and gradually increase it. This approach, supported by the TRADE study, is better tolerated than starting at the full dose, improving patient adherence and quality of life.
ESR1 mutations are not benign; they powerfully increase metastatic potential and liver tropism. This biological aggressiveness provides a strong rationale for proactive treatment upon ctDNA detection (as in SERENA-6) rather than waiting for radiographic progression and clinical symptoms.
For patients with aggressive, visceral disease (especially liver mets) progressing after a first-line CDK4/6 inhibitor, the gedatolisib triplet may be superior. Its ~9-month PFS in PIK3CA-mutant patients surpasses the ~5.5-month PFS seen with capivasertib in a similar pretreated population.
For lower-risk Stage 2/3 HER2+ breast cancer, clinicians can start with THP, assess response via MRI, and only then proceed to TDXD if necessary. This risk-stratified approach to the DESTINY-Breast11 regimen can spare some patients the unique toxicities of TDXD.
KEYNOTE-522 data shows that achieving pathologic complete response (path CR) with pembrolizumab offers a greater survival benefit than achieving path CR with chemotherapy alone. This suggests immunotherapy provides a lasting benefit beyond just initial tumor eradication.
For TNBC patients who achieve a pathologic complete response but experience a significant autoimmune flare during neoadjuvant therapy, it is reasonable to omit the adjuvant portion of pembrolizumab. The risk-benefit calculation shifts, as the added benefit is smaller post-path CR while toxicity risk is proven.
In metastatic TNBC, using sacituzumab govitecan (SG) first-line provides a progression-free survival (PFS) advantage that cannot be regained by using it second-line after initial chemotherapy. The PFS2 data from ASCENT trials shows starting with SG is definitively better than a chemo-first sequence.
Oncologists view datopotamab deruxtecan and sacituzumab govitecan as similarly effective for first-line TNBC. The choice is driven by side effect profiles: stomatitis/ILD with Dato versus alopecia/GI toxicity with SG, and logistics like infusion frequency.
Tumors with low ER positivity (e.g., 20%) but aggressive features like high Ki-67 should undergo intrinsic subtyping. If identified as "basal-like," they should be treated like triple-negative breast cancer with regimens such as KEYNOTE-522, overriding standard IHC classification.
For patients developing grade 2 stomatitis on datopotamab deruxtecan, dose reduction is a critical and highly effective strategy to manage toxicity and allow them to continue treatment. This is often more impactful than supportive measures alone.